San Diego biotech secures $75M to advance lead candidate

Arthrosi Ther­a­peu­tics, a biotech com­pa­ny de­vel­op­ing a gout treat­ment, raised a fresh $75 mil­lion through a Se­ries D round.

Ac­cord­ing to a press re­lease on Tues­day, Guan­grun Health In­dus­try led the round along­side oth­er in­vestors, in­clud­ing Re­ich­stein Biotech, a sub­sidiary of Api­cHope Phar­ma­ceu­ti­cals. Arthrosi hasn’t shared news about pre­vi­ous fi­nanc­ing rounds, but da­ta from Pitch­Book show that this was the sev­enth round. It last raised $15 mil­lion in March and has raised a to­tal of $154.1 mil­lion, ac­cord­ing to Pitch­Book.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN